Sol-gel's collaboration partner first-to-file anda drug product generic to zoryve® cream

Ness ziona, israel, april 01, 2024 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a phase 3 clinical trial of sgt-610 (patidegib gel, 2%) for gorlin syndrome, and with two approved large-category dermatology products, twyneo® and epsolay®, today announced that padagis israel pharmaceuticals ltd (“padagis”), sol-gel's collaboration partner, submitted a first-to-file abbreviated new drug application (“anda”) to the u.s. food and drug administration (“fda”) for roflumilast cream, 0.3%, a drug product generic to zoryve® cream (roflumilast cream, 0.3%), indicated for the treatment of plaque psoriasis in patients six years of age and older.
SLGL Ratings Summary
SLGL Quant Ranking